{"entity":{"id":"nct06787664","kind":"trial","name":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma","aka":[],"tldr":"A phase 2 trial of Izalontamab brengitecan in chordoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.","summary":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma is a phase 2 interventional study registered as NCT06787664 by Sichuan Baili Pharmaceutical Co., Ltd., with 27 participants enrolled, started 2025-01-16 and due to reach its primary completion in 2027-06. Interventions recorded: BL-B01D1. Conditions listed: Chordoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06787664","url":"https://clinicaltrials.gov/study/NCT06787664"}],"tags":["ctgov-ingest"],"related":[],"cancers":["chordoma"],"sections":[],"technologies":["adc","bispecific-adc"],"targets":[],"drugs":["izalontamab-brengitecan"],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06787664","phase":"2","setting":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 for Injection in Patients With Locally Advanced or Metastatic Chordoma","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","participation":[{"nct":"NCT06787664","source":"https://clinicaltrials.gov/study/NCT06787664","fetchedAt":"2026-10-07T16:55:03.017Z","studySha256":"b75df30d81b4b992941785f6ab12091029554f213a659224d6ffbda2cc4eb474","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-04-13","leadSponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":27,"enrolmentType":"ACTUAL","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2025-01-16","startedType":"actual","enrolled":27,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06787664/","neighbours":{"cancer":[{"id":"chordoma","kind":"cancer","name":"Chordoma","route":"/cancers/chordoma/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/"}],"drug":[{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}